Month: August 2024

Release – V2X Secures $747 Million Contract for Crucial F-5 Aircraft Maintenance, Boosting Navy Readiness

Posted on by dburczyk@noblecapitalmarkets.com

MCLEAN, Va., Aug. 26, 2024 /PRNewswire/ — V2X, Inc. (NYSE: VVX) announces that it has been awarded a single award indefinite-delivery/indefinite-quantity contract valued at $747 million. The F-5 aircraft play a crucial role in training naval pilots by providing adversary combat tactics and simulation capabilities. This advanced training environment ensures that pilots are well-prepared for real-world scenarios, enhancing their combat readiness and proficiency. The use of F-5s in an aggressor-training role contributes significantly to the overall readiness of our armed forces, ensuring they are equipped with the skills and experience needed to protect the nation effectively.

This contract underscores V2X’s commitment to supporting our nation’s military readiness and ensuring the sustainability of these essential assets.

“We are honored to have been selected for this critical endeavor, further solidifying our dedication to providing industry leading support for our nation’s defense,” said Jeremy C. Wensinger, President and Chief Executive Officer at V2X. “We look forward to leveraging our expertise and capabilities to ensure the operational excellence of the F-5 aircraft and, by extension, the readiness of the U.S. Navy and Marine Corps.”

V2X will be responsible for delivering critical support and operational readiness of the F-5 Adversary aircraft. The work will encompass multiple locations across the United States.

Under this firm-fixed price contract, the comprehensive scope of services is projected to continue through November 2028 on the base contract, with three one-year options that could extend through November 2031, bringing the overall contract value to more than $747 million.

About V2X

V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@goV2X.com
571-338-5195

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-secures-747-million-contract-for-crucial-f-5-aircraft-maintenance-boosting-navy-readiness-302230359.html

SOURCE V2X, Inc.

Powell Signals Fed Ready to Start Lowering Interest Rates

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Federal Reserve Chair Jerome Powell indicates a readiness to cut interest rates, signaling a shift in monetary policy direction.
– The Fed’s anticipated rate cut, likely to be announced at the September meeting, reflects recent economic data showing a softer labor market.
– Powell’s remarks highlight progress in controlling inflation and managing economic distortions from the COVID-19 pandemic.

In a pivotal address at the Kansas City Fed’s annual economic symposium in Jackson Hole, Wyoming, Federal Reserve Chair Jerome Powell delivered a clear message to the financial markets: “The time has come” to begin cutting interest rates. This statement marks a significant shift in monetary policy and provides insight into the Fed’s response to evolving economic conditions.

Powell’s speech, delivered on August 23, 2024, comes as anticipation builds for the Federal Reserve’s upcoming meeting scheduled for September 17-18. Investors are now almost certain that the central bank will implement its first interest rate cut since 2020. Powell’s remarks reflect a response to recent economic data and shifting conditions in the labor market.

One of the key factors influencing the Fed’s decision is the recent softness in the labor market. The July jobs report revealed that the U.S. economy added only 114,000 jobs, and the unemployment rate rose to 4.3%, the highest level since October 2021. Additionally, data indicating a reduction of 818,000 jobs from earlier in the year suggests that previous employment figures may have overstated the labor market’s strength. Powell acknowledged these developments, emphasizing that the Fed does not anticipate further cooling in labor market conditions contributing to elevated inflationary pressures.

Powell’s speech underscored the progress made in addressing inflation, a primary focus of the Fed’s recent monetary policy. “Four and a half years after COVID-19’s arrival, the worst of the pandemic-related economic distortions are fading,” Powell stated. He noted that inflation has significantly declined and attributed this improvement to the Fed’s efforts to moderate aggregate demand and restore price stability. This progress aligns with the Fed’s goal of maintaining a strong labor market while achieving its 2% inflation target.

Powell’s tone marked a notable contrast from his speech at Jackson Hole in 2022, where he discussed the potential for economic pain due to high unemployment and slow growth as part of the effort to control inflation. At that time, Powell was more focused on the possibility of a recession and the need for persistent high interest rates to combat inflation. The current shift towards rate cuts suggests that the Fed believes the economic landscape has improved sufficiently to warrant a change in policy.

As Powell outlined, the timing and pace of future rate cuts will depend on incoming data and the evolving economic outlook. The Fed’s approach will be data-driven, reflecting a careful balance between fostering economic growth and managing inflation. This flexibility underscores the Fed’s commitment to adapting its policies in response to changing economic conditions.

In summary, Powell’s recent address signals a significant policy shift as the Fed prepares to cut interest rates for the first time in several years. This move reflects the central bank’s confidence in the progress made towards economic stability and inflation control. The upcoming September meeting will be crucial in determining the exact nature of these rate adjustments and their implications for the broader economy.

Release – Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on TNXP

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

CHATHAM, NJ / ACCESSWIRE / August 23, 2024 / Following an upsurge of cases in the Democratic Republic of the Congo and several other countries in Africa, the World Health Organization (WHO) declared mpox a public health emergency of international concern on Aug. 14 – the second such declaration in two years. The WHO has called on vaccine manufacturers to step up efforts to curb the spread of a new, more deadly strain of the virus.

The WHO also is asking companies and organizations to bring in their vaccines, inviting developers of mpox vaccines to submit an Expression of Interest for Emergency Use Listing (EUL).

Amid this backdrop, Tonix Pharmaceuticals (NASDAQ:TNXP) is developing a vaccine candidate, called TNX-801, that could play a role in combating this escalating global health crisis. Tonix has successfully completed non-human primate studies showing protection from challenge with lethal doses of the Clade 1 monkeypox virus that is driving the new epidemic.

Clearly more testing is ahead for TNX-801, but the technology behind it is rooted in the science of Edward Jenner’s smallpox vaccine of the late 1700s, the only vaccine to successfully eradicate a contagious viral pathogen.

These credentials have earned the vaccine technology platform upon which TNX-801 is based a competitive spot in the NIH’s NextGen program for a more effective, single-dose COVID-19 vaccine to potentially provide durable protection instead of the every-six month booster strategy of mRNA vaccines.

Last month, another of Tonix’s technologies was awarded a contract for up to $34 million by the U.S. Department of Defense to develop a single broad spectrum antiviral that would work against multiple potential biowarfare agents.

An Historical Approach to Modern Challenges
The current mpox crisis can be traced back to a decision made in the 1970s to discontinue routine smallpox vaccinations after smallpox was successfully eradicated. Research shows that the smallpox vaccine also provided immunity against mpox. In retrospect, smallpox vaccination kept mpox out of the human population in Africa. So an unintended consequence of stopping vaccinations for smallpox meant that mpox, then known as monkeypox (which is still the name of the virus), was able to reemerge in the human population.

Tonix’s mpox vaccine is believed to be closely related to the original smallpox vaccine invented by British physician Edward Jenner in 1796. Jenner’s vaccine is credited with being the first and only vaccine to successfully eradicate a viral pathogen. This triumph depended on several important attributes of the vaccine, including that it was generally well-tolerated, provided long-term immunity with a single dose, prevented forward transmission and provided a simple biomarker confirmation of protective immunity known as a “take”.

TNX-801 is designed to have these same attributes; it is delivered in a single dose that provides protective immunity to animals that is marked by a “take”. It is believed to have a high likelihood of providing durable immunity and preventing forward transmission. Furthermore, unlike many other vaccines, TNX-801 does not require complex ultra cold-chain storage, making it a strong candidate for global distribution.

The Science Behind TNX-801
Unlike mRNA vaccines, which primarily elicit an antibody response that requires frequent booster shots, TNX-801 is designed to trigger a robust T-cell response. T-cells have the ability to recognize and remember internal parts of viral proteins, not just those on the surface. T-cell memory lasts for years – even decades – providing long-term immunity and potentially eliminating the need for repeated boosters.

In preclinical trials, Tonix says TNX-801 demonstrated the ability to prevent death, clinical disease and lesions caused by a lethal challenge of monkeypox virus in non-human primates. Similar to Jenner’s smallpox vaccine, TNX-801 also significantly reduced viral shedding, suggesting that it can block forward transmission,. Tonix is rushing to manufacture vaccine suitable for Phase 1 human trials.

Beyond Mpox: A Platform for Future Pandemics
The vaccine platform on which TNX-801 is based has potential applications beyond mpox. The company says the TNX-1800 version of the platform, for example, is designed to protect against COVID-19 and has shown promise in preclinical studies. The U.S. National Institute of Health has recognized the potential of Tonix’s platform by selecting it for Project NextGen, aimed at developing next-generation COVID-19 vaccines and pandemic platform technologies.

As the world faces the growing threat of mpox and other infectious diseases, Tonix Pharmaceuticals is not only attempting to address the current crisis with TNX-801, but also potentially contributing to a future where pandemics can be more predictably contained.

Featured photo by Gilnature on iStock.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Click here for more information on Tonix Pharmaceuticals: https://redingtonvirtual.com/tnxp-aw-24082/

Investor Contact
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

SOURCE: Tonix Pharmaceuticals Holding Corp.

MustGrow Biologics Corp. (MGROF) – Another State Added

Posted on by cpereira@noblefcm.com


Friday, August 23, 2024

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A New State. On the heels of Idaho’s approval of TerraSante earlier in the month, MustGrow announced receipt from the Arizona Department of Agriculture for the registration approval of its TerraSante product. The approval will give MustGrow the ability to commence sales within the state. Arizona now joins a list that includes four other states in the aforementioned Idaho, Oregon, California, and Washington State.

Synergy with California. Arizona’s approval is key with the Company’s commercialization strategy with BioAg Product Strategies. In the winter months, agriculture companies in California use the winter climate in Arizona for its winter farming production. We believe that the Company can ‘double-dip’ in potential sales to farming companies looking to use MustGrow’s products for both California and Arizona, providing increased revenue.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Elections and the Stock Market: Navigating the 2024 US Presidential Race

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– The 2024 US election may increase market volatility
– Policy proposals could impact various economic sectors
– Long-term investment strategies remain crucial despite short-term political events

As the 2024 US presidential election approaches, investors are keenly watching how the political landscape might influence their portfolios. With election day set for November 5, 2024, understanding the potential impacts of this specific election cycle on the financial markets is crucial for informed decision-making.

The 2024 election is particularly significant as it follows a period of economic uncertainty, including high inflation and interest rates. Investors are closely monitoring how candidates’ policies might address these issues and shape the economic landscape moving forward.

Several key policy areas are under scrutiny. Proposals for corporate tax rates and capital gains taxes could significantly impact company profits and investor returns. Potential changes in regulatory frameworks, especially in sectors like technology, finance, and energy, may affect industry leaders and emerging companies alike. Government spending plans, including infrastructure initiatives, healthcare reforms, and climate policies, could influence various sectors of the economy. Additionally, stances on international trade, particularly regarding relationships with China and other major economic partners, may affect global markets and supply chains.

As we move closer to November, expect increased market volatility. The VIX index, often called the “fear gauge” of the market, typically rises during election years, and 2024 is likely to follow this pattern. However, it’s crucial to remember that while short-term fluctuations can be unsettling, they often have little bearing on long-term market trends.

Current polls and predictions should be taken with a grain of salt. The 2016 and 2020 elections demonstrated that unexpected outcomes are possible, and markets can react swiftly to surprises. Investors should be prepared for potential market movements in either direction as election day approaches and results unfold.

Specific sectors to watch in this election cycle include healthcare, energy, technology, and financial services. Healthcare proposals could significantly impact insurance companies, pharmaceutical firms, and hospital operators. Energy policies on fossil fuels, renewable energy, and climate change may cause shifts in the sector. In technology, discussions around data privacy, antitrust measures, and AI regulation could affect tech giants and emerging companies. Financial services may see changes due to potential shifts in banking regulations and monetary policy approaches.

For investors navigating this election season, several strategies are worth considering. Reviewing your asset allocation ensures your portfolio is well-diversified and aligned with your long-term goals, regardless of the election outcome. While staying informed is important, avoid overreacting to polls or predictions. If you’re concerned about volatility, focusing on defensive sectors like utilities and consumer staples can provide more stability during uncertain times.

Market overreactions to political news can sometimes create buying opportunities for long-term investors. It’s also crucial to maintain a global perspective, remembering that many US companies derive significant revenue from overseas, potentially mitigating the impact of domestic policy changes.

As November 5 approaches, it’s natural to feel uncertainty about the markets. However, historical data shows that elections typically have a limited long-term impact on market performance. Regardless of the outcome, the fundamentals of sound investing remain the same: focus on your long-term goals, stay diversified, and avoid making emotional decisions based on short-term political events.

In conclusion, while the 2024 US presidential election will undoubtedly create some market waves, it’s crucial to maintain perspective. By staying informed, prepared, and focused on your long-term investment strategy, you can navigate this election season with confidence. Remember that beyond the election cycle, factors such as economic growth, corporate earnings, and technological advancements continue to be significant drivers of market performance in the long run.

Rail Chaos in Canada: Economic Tremors as Major Railways Lock Out Workers

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– CN and CPKC lock out over 9,000 unionized workers, halting rail operations
– Fears of billions in economic damage and supply chain disruptions across North America
– Work-life balance and scheduling at the core of the labor dispute

As the clock struck midnight on Thursday, Canada’s rail network screeched to a halt, plunging the country into an unprecedented crisis that threatens to derail its economy and send shockwaves through North American supply chains. The nation’s two railway giants, Canadian National Railway (CN) and Canadian Pacific Kansas City (CPKC), have locked out over 9,000 unionized workers, triggering a standoff that could cost billions and leave industries scrambling for alternatives.

The lockout comes after failed negotiations between the railway companies and the Teamsters Canada Rail Conference (TCRC), with both sides blaming each other for the breakdown in talks. At the heart of the dispute are issues surrounding scheduling, labor availability, and demands for improved work-life balance. The introduction of new duty and rest period rules by the Canadian government in 2023 has further complicated matters.

The economic impact of this rail stoppage is expected to be severe. Moody’s, a prominent ratings agency, estimates that the daily cost could exceed C$341 million ($251 million). The halt in rail operations is set to cripple shipments of vital commodities such as grain, potash, and coal, while also slowing the transport of petroleum products, chemicals, and automobiles. The repercussions are expected to extend beyond Canada’s borders, affecting businesses in the United States due to the highly integrated nature of the two economies.

Adding to the chaos, tens of thousands of commuters in major cities like Toronto, Vancouver, and Montreal have been left stranded as train movements on CPKC-owned commuter lines have ceased. This has prompted urgent calls from local officials, including Ontario Premier Doug Ford, for a swift resolution to the dispute.

The Canadian government has thus far refrained from invoking its power to force binding arbitration, instead urging the parties to continue negotiations. However, as the economic toll mounts, pressure is likely to increase on the government to intervene more directly.

For the locked-out workers, primarily conductors, locomotive engineers, and yard workers, the core issues revolve around work schedules and rest periods. CN’s proposal to extend shifts up to 12 hours, in line with government norms, has met strong resistance from the union. Workers are particularly concerned about the potential reduction of rest periods and the unpredictable nature of on-call work.

As picket lines form and negotiations continue, the broader implications of this dispute are becoming increasingly apparent. Analysts predict significant hits to the profits of both CN and CPKC, with each day of the lockout estimated to impact earnings per share.

This unprecedented rail stoppage serves as a stark reminder of the critical role transportation infrastructure plays in the North American economy. As businesses, commuters, and government officials grapple with the fallout, all eyes remain on the negotiating table, hoping for a swift resolution to this disruptive and costly labor dispute.

Release – Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on CVKD

PONTE VEDRA, Fla., Aug. 22, 2024 — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, announced today that it will be engaging with the U.S. Food and Drug Administration (FDA) in early September for a Type-B meeting to discuss its clinical trial for tecarfarin in LVAD patients.

“This upcoming meeting with the FDA is a crucial step in developing tecarfarin as we prepare for our pivotal trial. We look forward to discussing the development program for tecarfarin in LVAD patients,” said Quang Pham, Chief Executive Officer of Cadrenal Therapeutics.

ABOUT LVAD PATIENTS

Left Ventricular Assist Devices (LVADs) are mechanical pumps to support heart function in patients with advanced heart failure. These devices are vital for patients awaiting heart transplants or those who are ineligible for transplants. However, LVAD patients face an increased risk of thromboembolic events, such as strokes, which necessitates ongoing anticoagulation therapy. The current anticoagulation therapy, warfarin, presents challenges, including variability in dosing, a narrow therapeutic window, and potential interactions with other medications, making effective management crucial to reducing complications and ensuring patient safety.

ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions. Tecarfarin has orphan drug designation for the prevention of thrombosis and thromboembolism in patients with ventricular assist devices. Tecarfarin also has orphan drug and fast-track designations from the FDA for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease and atrial fibrillation. Cadrenal is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has been evaluated in 11 human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.

SAFE HARBOR STATEMENT

Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the Company engaging with the FDA in early September for a Type-B meeting to discuss its clinical trial for tecarfarin in LVAD patients and the planned pivotal trial. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to improve anticoagulation treatment in patients, the success of the Type-B meeting, the ability of the Company to commence and complete a pivotal trial and commercialize tecarfarin with patients with left ventricular assist devices (LVADs), and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-announces-upcoming-type-b-fda-meeting-in-september-to-discuss-tecarfarin-trial-in-lvad-patients-302228174.html

SOURCE Cadrenal Therapeutics, Inc.

Release – MustGrow Receives Arizona Registration for TerraSanteTM Biofertility Product

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on MGROF

  • MustGrow has received the Arizona Department of Agriculture approval to commence sales of TerraSanteTM, an organic biofertility product, in the State of Arizona.
  • Mustard-derived TerraSanteTM focuses on soil and soil microbiome health, nutrient/water use efficiencies, and plant yields.

SASKATOON, Saskatchewan, Canada, August 22, 2024 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow”) is pleased to announce receipt of the Arizona Department of Agriculture registration approval for its mustard plant-based TerraSanteTM, an organic biofertility product. The Arizona organic certification is included under MustGrow’s existing Organic OMRI Listed® certifications in Idaho, Oregon, and Washington State.

MustGrow’s Arizona registration and organic certification is a key pillar in the commercialization strategy with BioAg Product Strategies. Notably, several large California agriculture companies utilize Arizona’s winter climate for winter farming production. In addition to Arizona, and recently-awarded Idaho, California, Oregon and Washington State, MustGrow expects to continue its efforts towards further state-level registrations in other pertinent U.S. states.

With over 25 million acres of farmland, Arizona farms produced US$3.0 billion in agricultural crop products in 2022.1 The Vegetable/Melon/Potatoes category led with US$1.43 billion in sales.2 Arizona is ranked 2nd in the U.S. production for head lettuce, leaf lettuce, romaine lettuce, cauliflower, broccoli, spinach, and cantaloupe. Yuma County is considered the winter lettuce capital of the world, also highly regarded for its leafy greens, broccoli, and cauliflower.3

TerraSanteTM for Soil and Ecological Health

MustGrow’s soil amendment and biofertility development programs focus on soil and soil microbiome health, nutrient and water use efficiencies, and plant yields. Soil is a farmer’s most valuable asset, and MustGrow’s mustard plant-based technologies are being developed with the intention to improve not only the health of the soil, but also the surrounding ecological environment.

As an organic biofertilizer in soluble mixable form, TerraSanteTM contains nutritious plant proteins and carbohydrates that feed the soil and soil microbes, potentially improving beneficial microbial activity and ensuring long-term sustainable soil health. These targeted micro-communities have been shown to work to improve nutrient availability, which can potentially increase plant vigor and yields, while reducing plant stress. TerraSanteTM has the potential to improve crop nutrient uptake and, hence, overall crop performance. There are no artificial additives or preservatives used during its manufacturing.

To learn more about TerraSanteTM, visit www.mustgrow.ca

Sources:
1. https://farmflavor.com/arizona/arizona-crops-livestock/top-arizona-agriculture-facts/
2. https://www.azfb.org/Article/Arizona-Results-from-the-2022-Census-of-Agriculture
3. https://blog.aghires.com/arizona-ag-facts/

About MustGrow

MustGrow is an agriculture biotech company developing organic biocontrol and biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world. MustGrow and its leading global partners — Bayer, Janssen PMP (pharmaceutical division of Johnson & Johnson), Sumitomo Corporation, and Univar Solutions’ NexusBioAg — are developing mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Bayer has a commercial agreement to develop and commercialize MustGrow’s biocontrol soil applications in Europe, Africa, and the Middle East.  Concurrently, with new formulations derived from food-grade mustard, the Company is pursuing the adoption and use of its Organic Materials Review Institute (OMRI Listed®) and California’s Organic Input Material (OIM) Program registered biofertility product, TerraSanteTM, in key U.S. states including California. Over 150 independent tests have been completed, validating MustGrow’s safe and effective approach to crop and food protection and yield enhancements. Pending regulatory approval, MustGrow’s patented liquid technologies could be applied through injection, standard drip or spray equipment, improving functionality and performance features. MustGrow has approximately 51.6 million basic common shares issued and outstanding and 54.1 million shares fully diluted.  For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: its commercialization strategy; its continuing efforts towards further state-level registrations; TerraSanteTM ability to improve beneficial microbial activity; the ability of TerraSanteTM to increase plant vigor and yields; and the ability of TerraSanteTM to improve crop nutrient uptake. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include market receptivity to investor relations activities as well as those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release. © 2024 MustGrow Biologics Corp. All rights reserved.

Bitfarms’ Bold Move to Acquire Stronghold Digital Mining

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Bitfarms to acquire Stronghold Digital Mining in a $175 million deal
– Merger expands Bitfarms’ U.S. presence and power capacity significantly
– Transaction aims to boost environmental efforts and diversify beyond Bitcoin mining

Bitfarms Ltd. has announced its plans to acquire Stronghold Digital Mining, Inc. in a deal valued at approximately $175 million in a strategic move that’s set to reshape the Bitcoin mining landscape. This bold acquisition, slated to close in the first quarter of 2025, marks a significant milestone in Bitfarms’ growth strategy and signals a new era for both companies in the ever-evolving cryptocurrency sector.

The all-stock transaction will see Stronghold shareholders receive 2.52 Bitfarms shares for each Stronghold share they own, representing a 71% premium based on recent trading prices. This merger is poised to create a powerhouse in the Bitcoin mining industry, combining Bitfarms’ operational expertise with Stronghold’s strategic assets and power generation capabilities.

At the heart of this acquisition is Bitfarms’ ambition to expand and rebalance its energy portfolio. The company aims to increase its presence in the United States dramatically, projecting that nearly 50% of its 950 MW energy capacity will be based in the U.S. by the end of 2025. This move aligns with Bitfarms’ strategic plan to diversify geographically and tap into new power sources.

Stronghold brings to the table 4.0 EH/s of current hashrate, with the potential to scale up to approximately 10 EH/s in 2025 through fleet upgrades. The acquisition also includes two merchant power plants in Pennsylvania, providing 165 MW of nameplate generated power capacity. These facilities are recognized for their environmental benefits, converting mining waste into power and contributing to land reclamation efforts.

Perhaps most intriguing is the transaction’s potential to propel Bitfarms beyond traditional Bitcoin mining. The company sees opportunities to leverage high-performance computing (HPC) and artificial intelligence (AI) capabilities, potentially merging these technologies with their Bitcoin mining operations. This diversification strategy could open new revenue streams and position the combined entity at the forefront of technological innovation in the crypto space.

Environmental considerations play a crucial role in this merger. Stronghold’s reclamation facilities have already rehabilitated thousands of acres of toxic waste sites, addressing historical environmental issues dating back to the 1800s. Furthermore, the potential for carbon capture projects could position Bitfarms as a leader in sustainable cryptocurrency mining practices.

The merger is expected to yield significant synergies, with an estimated $10 million in annual run-rate cost savings. This efficiency boost, coupled with the expanded power capacity and technological capabilities, positions the combined company to weather the cyclical nature of the cryptocurrency markets more effectively.

However, the road ahead is not without challenges. The transaction still requires approval from Stronghold shareholders and various regulatory bodies. Additionally, the volatile nature of cryptocurrency prices and the ever-changing regulatory landscape pose ongoing risks to the industry.

As the crypto mining sector continues to mature and face increased scrutiny over its energy consumption, this merger represents a forward-thinking approach to addressing both economic and environmental concerns. By vertically integrating power generation, expanding into strategic locations, and focusing on sustainable practices, Bitfarms is positioning itself as a leader in the next generation of cryptocurrency mining operations.

In conclusion, the Bitfarms-Stronghold merger is more than just a consolidation of assets; it’s a strategic bet on the future of Bitcoin mining and digital asset infrastructure. As the industry evolves, this union could serve as a blueprint for how cryptocurrency companies can adapt, grow, and contribute positively to both technological advancement and environmental stewardship.

The Troubling Revision: U.S. Employment Figures Adjusted Downward by 818,000

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Significant downward adjustment in U.S. employment data
– Diverging views on implications of backward-looking data
– Labor market concerns shape Fed’s policy path forward

The U.S. economy employed 818,000 fewer people than originally reported as of March 2024, according to a government revision. This substantial adjustment suggests the labor market may have been cooling much earlier than initially thought.

The Bureau of Labor Statistics’ annual data revision showed the largest downward changes in the professional and business services industry, which saw a reduction of 358,000 jobs, and the leisure and hospitality sector, which experienced a 150,000 job cut. These revisions move the monthly job additions down to 174,000 from the initial 242,000.

While Omair Sharif of Inflation Insights described the adjusted growth rate as “still a very healthy” one, the revised figures raise concerns about the true state of the labor market. Economists, however, caution against overreacting, noting that the realization of fewer jobs created “does not change the broader trends” in the economy.

The timing of this revision is particularly significant, as recent signs of labor market slowing have fueled debates about the Federal Reserve’s monetary policy stance. The weak July jobs report and the rise in the unemployment rate, which triggered a recession indicator, have prompted discussions about the appropriate course of action.

As Federal Reserve Chair Jerome Powell prepares to speak at the Jackson Hole Symposium, the labor market is expected to be a key focus. Economists anticipate Powell may express more confidence in the inflation outlook while highlighting the downside risks in the labor market, potentially paving the way for a series of interest rate cuts in the coming months.

The diverging perspectives on the employment data revision underscore the complexities in interpreting economic signals and their potential impact on policymaking. As the U.S. economy navigates a delicate balance between slowing growth and persistent inflationary pressures, the employment data revision serves as a stark reminder of the need for a nuanced, data-driven approach to economic decision-making. Furthermore, the size of the revision highlights the importance of closely monitoring and accurately measuring the labor market, as these figures play a crucial role in guiding policymakers and shaping economic strategies.

Release – V2X Secures $3.7 Billion Task Order to Spearhead Next-Generation Readiness and Training Capabilities for U.S. Army Worldwide

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on VVX

MCLEAN, Va., Aug. 21, 2024 /PRNewswire/ — V2X, Inc. (NYSE: VVX) announces a mission critical win to provide readiness capabilities to the U.S. Army worldwide under the Warfighter-Training Readiness Solutions (W-TRS) task order. Valued at $3.7 billion over five years, including option periods, this task order further solidifies V2X’s leading role in enabling full spectrum readiness for every soldier and unit across the U.S. Army.

At the heart of this initiative is the mission enablement services for the Army’s expansive network of Training Aids Devices Simulations and Simulators (TADSS). V2X will provide a flexible enterprise solution that will seamlessly support hundreds of thousands of these critical devices worldwide, evolving warfighter training needs. 

“We are leading Army readiness with solutions that incorporate technology, techniques, and integration for a rapidly changing operational environment. W-TRS empowers the Army to  harness cutting-edge innovation swiftly, making sure our forces remain agile and prepared against all threats,” said Jeremy C. Wensinger, President and Chief Executive Officer at V2X. Wensinger reaffirmed V2X’s dedication to the strategic readiness of the Army, “This comprehensive effort ensures our warfighters are properly prepared to keep the nation safe and that our customers are enabled to execute missions around the globe.”

“V2X has a proven track record of providing high-consequence mission readiness to the Army, and we are honored the Army has continued to put their trust in V2X to ensure every soldier and unit in the Army has the tools they need to conduct realistic training so they are prepared whenever called upon to deploy,” said Ken Shreves, Senior Vice President of Global Mission Solutions at V2X. “This win underscores V2X’s commitment to delivering comprehensive, end-to-end solutions throughout the entire mission lifecycle.” 

For decades, V2X has partnered with the U.S. Army at two of its four Combat Training Centers: the National Training Center in Fort Irwin, California, and the Joint Multinational Readiness Center in Germany. We continue to provide solutions to U.S. Army Central Command in Kuwait. V2X’s dedication to supporting the U.S. Army extends beyond operational excellence to safeguarding national security through robust mission critical initiatives. As the premier mission solution partner for the Army, V2X ensures readiness across all global theaters, reinforcing our nation’s defenses during both peacetime and active operations. 

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains. 

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@goV2X.com
571-338-5195

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-secures-3-7-billion-task-order-to-spearhead-next-generation-readiness-and-training-capabilities-for-us-army-worldwide-302226964.html

SOURCE V2X, Inc.

NN Inc. (NNBR) – Some Insider Buying

Posted on by cpereira@noblefcm.com


Wednesday, August 21, 2024

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Insider Buying. We are always interested to see insider buying, especially around current trading levels for the stock. Last week, three NN directors acquired a total of 32,550 NNBR shares at average prices in the $3.41 to $3.64 range. Such concentrated open market purchases are a positive, in our view.

Insider 1. First up, on August 14th Director Joao Faria disclosed the purchase of 20,000 NNBR shares at an average cost of $3.41 per share. Mr. Faria now owns 277,843 NNBR shares. Prior to last week, Mr. Faria’s most recent open market purchase was back in May 2023 when he acquired 30,000 NNBR shares at an average cost of $1.74.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Hemisphere Energy (HMENF) – Second Quarter Financial Results Exceed Expectations; Increasing Estimates

Posted on by cpereira@noblefcm.com


Wednesday, August 21, 2024

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Second quarter financial results. Hemisphere Energy reported second-quarter net income of C$10.4 million or C$0.10 per share compared to $5.8 million or $0.06 per share during the prior year period. We had forecast net income of C$9.5 million or C$0.09 per share. Year-over-year, revenue rose 52.2% to C$28.9 million driven by an increase in average daily production to 3,628 barrels of oil equivalent per day (BOE/d) compared to 2,883 during the prior year quarter and our estimate of 3,500. The average sales price per BOE increased to C$87.65 compared to C$72.48 in the second quarter of 2023. Adjusted funds flow from operations increased to C$13.6 million compared to C$8.1 million during the prior year period.

Updating estimates. We increased our 2024 adjusted funds flow (AFF) and earnings per share (EPS) estimates to C$45.4 million and C$0.35, respectively, from C$44.3 million and C$0.34. Our revisions are driven by the better than expected second quarter financial results. Our third and fourth quarter production estimates of 3,600 and 3,775 BOE/d are unchanged. We have increased our 2025 production estimate to 3,625 BOE/d from 3,504 and raised our AFF and EPS estimates to C$42.6 million and C$0.32, respectively, from C$41.1 million and C$0.30.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.